Anastrozole

AUG 19, 2026 · PHASE 3 TRIAL

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

ClinicalTrials.gov

This is an active Phase 3 trial registration with no reported results; the study design and primary endpoint are specified but outcome data are not yet available.

AUG 13, 2026 · PHASE 3 TRIAL

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

ClinicalTrials.gov

This is a registry record for an ongoing Phase 3 trial with no results yet reported; the study design is sound but evidence cannot be evaluated until data are available.

AUG 11, 2026 · PHASE 3 TRIAL

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results posted; the study design is sound but outcome data are not yet available to assess efficacy or safety.

AUG 10, 2026 · PHASE 3 TRIAL

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

ClinicalTrials.gov

This is an active Phase 3 trial registration with no results posted; the study is ongoing and has not yet reported efficacy or safety outcomes.

AUG 7, 2026 · PHASE 2 TRIAL

Endocrine Response in Women With Invasive Lobular Breast Cancer

ClinicalTrials.gov

Phase 2 interventional study of neoadjuvant endocrine therapy in a specific breast cancer subtype using a surrogate endpoint (Ki67 proliferative index); recruitment completed but results not yet reported in this registry record.